Table 1.

Comparison of patients treated or not treated with targeted curative COVID-19 treatment

Characteristic	Targeted curative treatment (n = 42; 81%)	No treatment (n = 10; 19%)	P value
Age, years, median (IQR)	52 (45–63)	55 (36–60)	0.71
Male sex, n (%)	23 (55)	7 (70)	0.49
Cause of immunosuppression, n (%)
Solid organ transplantation	29 (69)	6 (60)	0.71
Calcineurin inhibitor	23 (55)	6 (60)	1
Mycophenolate mofetil	21 (50)	5 (50)	1
Everolimus	11 (26)	1 (10)	0.42
Steroids	36 (86)	7 (70)	0.35
Belatacept	4 (10)	0 (0)	0.58
Rituximab	6 (14)	3 (30)	0.35
Other immunosuppressive agent	2 (5)	0 (0)	1
Cyclophosphamide	5 (12)	0 (0)	0.57
Active cancer with chemotherapy	3 (7)	0 (0)	1
Comorbidities
Diabetes mellitus, n (%)	19 (45)	3 (30)	0.49
Chronic heart failure, n (%)	4 (10)	0 (0)	0.58
Chronic respiratory failure, n (%)	1 (2)	0 (0)	1
Obesity, n (%)	8 (19)	3 (30)	0.42
eGFR, mL/min/1.73 m2, median (IQR)	55 (32–67)	55 (24–93)	0.69
End-stage renal disease with dialysis, n (%)	3 (7)	1 (10)	1
COVID-19 prophylaxis, n (%)
History of COVID-19	1 (2)	0 (0)	1
At least 3 doses of vaccine	35 (83)	7 (70)	0.38
Anti-S >264 BAU/mL	1 (3)	2 (22)	0.086
Casirivimab/imdevimab PREP	14 (33)	4 (40)	0.72
Tixagevimab/cilgavimab PREP	0 (0)	0 (0)	—
COVID-19 disease
Asymptomatic, n (%)	2 (5)	2 (20)	0.16
Fever, n (%)	26 (62)	5 (50)	0.5
Cough, n (%)	28 (67)	6 (60)	0.72
Dyspnoea, n (%)	15 (36)	3 (30)	1
Oxygen requirement, n (%)	5 (12)	3 (30)	0.17
Hospitalization, n (%)	12 (29)	3 (30)	1
Intensive care, n (%)	2 (5)	2 (20)	0.17
Death from COVID-19, n (%)	0 (0)	2 (20)	0.034
Follow-up duration, days, median (IQR)	63 (55–85)	59 (46–90)	0.62

Patients who received tocilizumab and other non-SARS-CoV-2-targeted treatments only are listed in the no-treatment column. Patients receiving PREP at least 5 days before symptom onset were excluded from this analysis.